Skip to main content

Table 3 Combination antibody therapies under investigation

From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Start year for vaccine trials including mAB combinations
  Start year 1997 1998 1999 2000 2001 2002 2004 2005 2006 2008 2009 2010 2011 2012 2013 2014 2015 Total
Anti-idiotypic antibody 3H1      1              1
 Lung     1              1
BEC2 mab 1 1                2
 Lung 1 1                2
Racotumomab           1       1
 NSCLC            1       1
Targeted Bevacizumab           1 2   1 1    5
 Brain               1    1
 Colorectal Cancer           1       1
 Lung            1       1
 Ovarian Cancer             1     1
 Renal Cell Cancer (RCC)         1        1
Cetuximab        1      1      2
 Colorectal Cancer            1      1
 Pancreatic Cancer       1           1
Erlotinib             1      1
 NSCLC             1      1
Trastuzumab (Herceptin)     1 1 1 1 1    1 1    7
 Breast Cancer      1 1 1 1 1    1 1    7
Rituximab    1    2   1   2        6
 Leukemia         1          1
 Lymphoma   1    2     2        5
Immune-suppressive Daclizumab             1      1
 Melanoma             1      1
muromonab-CD3 2       1            3
 Brain 1                  1
 Melanoma 1       1            2
Checkpoint inhibitor Ipilimumab      1 3   1       1 1   7
 Melanoma      1 3   1        1   6
 Pancreatic Cancer              1    1
nivolumab                 1 1
 Pancreatic Cancer                1 1
Pidilizumab (CT-011)          2 1 1     4
 Leukemia            1       1
 Myeloma            1       1
 Neoplasm              1     1
 Renal Cell Cancer (RCC)           1      1
  Total 2 1 1 1 1 1 7 2 3 1 4 5 4 3 3 1 1 41